Patents by Inventor Robert Matthew FESINMEYER

Robert Matthew FESINMEYER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240415929
    Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept. In some embodiments, the formulation comprises a Tris buffer.
    Type: Application
    Filed: September 3, 2024
    Publication date: December 19, 2024
    Applicant: AMGEN INC.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Rahul Rajan KAUSHIK
  • Publication number: 20240409611
    Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEGFR-Fc fusion protein is aflibercept.
    Type: Application
    Filed: August 28, 2024
    Publication date: December 12, 2024
    Applicant: Amgen Inc.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Monica Michelle GOSS, Sekhar KANAPURAM, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA
  • Patent number: 12156900
    Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: December 3, 2024
    Assignee: Amgen Inc.
    Inventors: Yael Wexler-Cohen, William J. Callahan, Robert Matthew Fesinmeyer, Rahul Rajan Kaushik, Sai Chakradhar Padala
  • Publication number: 20230025418
    Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEGFR-Fc fusion protein is aflibercept.
    Type: Application
    Filed: September 14, 2022
    Publication date: January 26, 2023
    Applicant: Amgen Inc.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Monica Michelle GOSS, Sekhar KANAPURAM, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA
  • Publication number: 20210353713
    Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept. In some embodiments, the formulation comprises a Tris buffer.
    Type: Application
    Filed: October 25, 2019
    Publication date: November 18, 2021
    Applicant: AMGEN INC.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Rahul Rajan KAUSHIK
  • Publication number: 20200352857
    Abstract: This invention concerns a series of excipients capable of effectively reducing the viscosity of protein formulations. The viscosity reducing excipients are oligopeptides (e.g., dipeptides, tripeptides) comprising at least one arginine. The peptides may also include basic or acidic or hydrophilic or hydrophobic/aromatic amino acids. An arginine residue may be either at the amino or the carboxyl end of the oligopeptide.
    Type: Application
    Filed: April 24, 2018
    Publication date: November 12, 2020
    Applicant: AMGEN INC.
    Inventors: Jian Hua GU, Robert Matthew FESINMEYER, Rulin QIAN
  • Publication number: 20200338164
    Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.
    Type: Application
    Filed: November 16, 2018
    Publication date: October 29, 2020
    Applicant: AMGEN INC.
    Inventors: Yael WEXLER-COHEN, William J. CALLAHAN, Robert Matthew FESINMEYER, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA
  • Publication number: 20200255496
    Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEG-FR-Fc fusion protein is aflibercept.
    Type: Application
    Filed: September 17, 2018
    Publication date: August 13, 2020
    Applicant: AMGEN INC.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Monica Michelle GOSS, Sekhar KANAPURAM, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA